CN108715822B - 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用 - Google Patents
一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用 Download PDFInfo
- Publication number
- CN108715822B CN108715822B CN201810606721.5A CN201810606721A CN108715822B CN 108715822 B CN108715822 B CN 108715822B CN 201810606721 A CN201810606721 A CN 201810606721A CN 108715822 B CN108715822 B CN 108715822B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus rhamnosus
- depression
- content
- reducing
- brain tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000218588 Lactobacillus rhamnosus Species 0.000 title claims abstract description 55
- 238000002360 preparation method Methods 0.000 title claims description 8
- 239000000935 antidepressant agent Substances 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 210000005013 brain tissue Anatomy 0.000 claims description 39
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 claims description 17
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 claims description 17
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 claims description 15
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 15
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 15
- 230000002757 inflammatory effect Effects 0.000 claims description 15
- 239000002858 neurotransmitter agent Substances 0.000 claims description 15
- 229940118019 malondialdehyde Drugs 0.000 claims description 13
- 210000002966 serum Anatomy 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000001430 anti-depressive effect Effects 0.000 abstract description 8
- 229940005513 antidepressants Drugs 0.000 abstract description 7
- 239000006041 probiotic Substances 0.000 abstract description 3
- 230000000529 probiotic effect Effects 0.000 abstract description 3
- 235000018291 probiotics Nutrition 0.000 abstract description 3
- 208000020016 psychiatric disease Diseases 0.000 abstract description 3
- 235000013305 food Nutrition 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 31
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 29
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 29
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 29
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 29
- 229960003147 reserpine Drugs 0.000 description 29
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 29
- 238000012360 testing method Methods 0.000 description 25
- 239000000047 product Substances 0.000 description 24
- 239000007924 injection Substances 0.000 description 21
- 238000002347 injection Methods 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 20
- 238000002965 ELISA Methods 0.000 description 16
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 16
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical group C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 16
- 230000001580 bacterial effect Effects 0.000 description 15
- 239000007928 intraperitoneal injection Substances 0.000 description 13
- 239000000725 suspension Substances 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 8
- 229960003638 dopamine Drugs 0.000 description 8
- 210000000744 eyelid Anatomy 0.000 description 8
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 8
- 229960002748 norepinephrine Drugs 0.000 description 8
- 210000000683 abdominal cavity Anatomy 0.000 description 7
- 230000036760 body temperature Effects 0.000 description 7
- GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 6
- 229960000389 fluoxetine hydrochloride Drugs 0.000 description 6
- 230000037396 body weight Effects 0.000 description 5
- 230000007267 depressive like behavior Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 201000003004 ptosis Diseases 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical group OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 108090000193 Interleukin-1 beta Proteins 0.000 description 4
- 102000003777 Interleukin-1 beta Human genes 0.000 description 4
- 241000186660 Lactobacillus Species 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 229940039696 lactobacillus Drugs 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 208000004130 Blepharoptosis Diseases 0.000 description 3
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- -1 ARBULIN Chemical compound 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 206010062575 Muscle contracture Diseases 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N aldehydo-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 208000006111 contracture Diseases 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000021108 sauerkraut Nutrition 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- AYRXSINWFIIFAE-UDKQPYHCSA-N (2r,3s,4r,5r)-2,3,4,5-tetrahydroxy-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexanal Chemical compound OC[C@H]1O[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-UDKQPYHCSA-N 0.000 description 1
- XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
- QXJDESBAUIILLG-UHFFFAOYSA-N 1,2,3,3,4,4,4-heptafluoro-1-iodobut-1-ene Chemical compound FC(I)=C(F)C(F)(F)C(F)(F)F QXJDESBAUIILLG-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- VBUYCZFBVCCYFD-JJYYJPOSSA-N 2-dehydro-D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)C(O)=O VBUYCZFBVCCYFD-JJYYJPOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N D-Arabitol Natural products OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- GUBGYTABKSRVRQ-UHFFFAOYSA-N D-Cellobiose Natural products OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- RFSUNEUAIZKAJO-VRPWFDPXSA-N D-Fructose Natural products OC[C@H]1OC(O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-VRPWFDPXSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HEBKCHPVOIAQTA-QWWZWVQMSA-N D-arabinitol Chemical compound OC[C@@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-QWWZWVQMSA-N 0.000 description 1
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-SOOFDHNKSA-N D-ribopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@@H]1O SRBFZHDQGSBBOR-SOOFDHNKSA-N 0.000 description 1
- LKDRXBCSQODPBY-OEXCPVAWSA-N D-tagatose Chemical compound OCC1(O)OC[C@@H](O)[C@H](O)[C@@H]1O LKDRXBCSQODPBY-OEXCPVAWSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- LKDRXBCSQODPBY-AMVSKUEXSA-N L-(-)-Sorbose Chemical compound OCC1(O)OC[C@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-AMVSKUEXSA-N 0.000 description 1
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 1
- HEBKCHPVOIAQTA-IMJSIDKUSA-N L-arabinitol Chemical compound OC[C@H](O)C(O)[C@@H](O)CO HEBKCHPVOIAQTA-IMJSIDKUSA-N 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- SRBFZHDQGSBBOR-OWMBCFKOSA-N L-ribopyranose Chemical compound O[C@H]1COC(O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-OWMBCFKOSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 101001033286 Mus musculus Interleukin-1 beta Proteins 0.000 description 1
- 101000648740 Mus musculus Tumor necrosis factor Proteins 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- DKXNBNKWCZZMJT-UHFFFAOYSA-N O4-alpha-D-Mannopyranosyl-D-mannose Natural products O=CC(O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O DKXNBNKWCZZMJT-UHFFFAOYSA-N 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HLCFGWHYROZGBI-JJKGCWMISA-M Potassium gluconate Chemical compound [K+].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O HLCFGWHYROZGBI-JJKGCWMISA-M 0.000 description 1
- NGFMICBWJRZIBI-JZRPKSSGSA-N Salicin Natural products O([C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O1)c1c(CO)cccc1 NGFMICBWJRZIBI-JZRPKSSGSA-N 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- QNHQEUFMIKRNTB-UHFFFAOYSA-N aesculetin Natural products C1CC(=O)OC2=C1C=C(O)C(O)=C2 QNHQEUFMIKRNTB-UHFFFAOYSA-N 0.000 description 1
- GUAFOGOEJLSQBT-UHFFFAOYSA-N aesculetin dimethyl ether Natural products C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- PNNNRSAQSRJVSB-BXKVDMCESA-N aldehydo-L-rhamnose Chemical compound C[C@H](O)[C@H](O)[C@@H](O)[C@@H](O)C=O PNNNRSAQSRJVSB-BXKVDMCESA-N 0.000 description 1
- PYMYPHUHKUWMLA-WISUUJSJSA-N aldehydo-L-xylose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WISUUJSJSA-N 0.000 description 1
- 229930195726 aldehydo-L-xylose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- SRBFZHDQGSBBOR-STGXQOJASA-N alpha-D-lyxopyranose Chemical compound O[C@@H]1CO[C@H](O)[C@@H](O)[C@H]1O SRBFZHDQGSBBOR-STGXQOJASA-N 0.000 description 1
- NGFMICBWJRZIBI-UHFFFAOYSA-N alpha-salicin Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UHFFFAOYSA-N 0.000 description 1
- 229940089837 amygdalin Drugs 0.000 description 1
- YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000002153 concerted effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000004049 epigenetic modification Effects 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- ILEDWLMCKZNDJK-UHFFFAOYSA-N esculetin Chemical compound C1=CC(=O)OC2=C1C=C(O)C(O)=C2 ILEDWLMCKZNDJK-UHFFFAOYSA-N 0.000 description 1
- YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- FBPFZTCFMRRESA-GUCUJZIJSA-N galactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-GUCUJZIJSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000009602 intrauterine growth Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ABXHMFFYSA-N melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-ABXHMFFYSA-N 0.000 description 1
- HOVAGTYPODGVJG-VEIUFWFVSA-N methyl alpha-D-mannoside Chemical compound CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O HOVAGTYPODGVJG-VEIUFWFVSA-N 0.000 description 1
- ZBDGHWFPLXXWRD-JGWLITMVSA-N methyl beta-D-xylopyranoside Chemical compound CO[C@@H]1OC[C@@H](O)[C@H](O)[C@H]1O ZBDGHWFPLXXWRD-JGWLITMVSA-N 0.000 description 1
- HOVAGTYPODGVJG-UHFFFAOYSA-N methyl beta-galactoside Natural products COC1OC(CO)C(O)C(O)C1O HOVAGTYPODGVJG-UHFFFAOYSA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000004766 neurogenesis Effects 0.000 description 1
- 230000004693 neuron damage Effects 0.000 description 1
- 210000000607 neurosecretory system Anatomy 0.000 description 1
- 239000003900 neurotrophic factor Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003189 potassium gluconate Drugs 0.000 description 1
- 239000004224 potassium gluconate Substances 0.000 description 1
- 235000013926 potassium gluconate Nutrition 0.000 description 1
- GSFHMOMWXNDPMM-YMDUGQBDSA-M potassium;(2r,3s,4s)-2,3,4,6-tetrahydroxy-5-oxohexanoate Chemical compound [K+].OCC(=O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O GSFHMOMWXNDPMM-YMDUGQBDSA-M 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000012113 quantitative test Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- HEBKCHPVOIAQTA-ZXFHETKHSA-N ribitol Chemical compound OC[C@H](O)[C@H](O)[C@H](O)CO HEBKCHPVOIAQTA-ZXFHETKHSA-N 0.000 description 1
- NGFMICBWJRZIBI-UJPOAAIJSA-N salicin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1CO NGFMICBWJRZIBI-UJPOAAIJSA-N 0.000 description 1
- 229940120668 salicin Drugs 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/175—Rhamnosus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明公开了一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用。本发明提供的鼠李糖乳杆菌TF318,保藏编号为CCTCC NO:M 2018113。本发明还保护鼠李糖乳杆菌TF318在制备抗抑郁产品中的应用。本发明还保护一种抗抑郁产品,其活性成分为鼠李糖乳杆菌TF318。所述产品为食品、保健品或药品。本发明提供的鼠李糖乳杆菌TF318具有抗抑郁功能,可作为预防和治疗抑郁症的功能性益生菌,为临床干预和控制抑郁症等相关的精神类疾病提供新的思路。
Description
技术领域
本发明涉及一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用。
背景技术
抑郁症是一种常见的、复杂的、可能危及生命的精神疾病。到目前为止,抑郁症的发病机理还没有完全阐述清楚,但是经过大量科研人员的共同努力,发现抑郁症的发生是由于复杂的信号网络的改变而引起的,这些网络覆盖单胺神经递质系统、神经内分泌系统、神经营养因子、神经发生、免疫系统的改变和表观遗传修饰等等,而遗传因素对抑郁症的发病机制也有相当大的贡献。
目前临床上治疗药物的开发主要基于“单胺假说”,这类药物对部分抑郁症患者(20-30%)无疗效,因此寻找更有效、更快速的预防和辅助治疗抑郁症的方法是非常必要的。
发明内容
本发明的目的是提供一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用。
本发明提供的鼠李糖乳杆菌TF318,全称为鼠李糖乳杆菌(Lactobacillusrhamnosus)TF318,已于2018年03月11日保藏于中国典型培养物保藏中心(简称CCTCC,地址为:中国,武汉,武汉大学),保藏编号为CCTCC NO:M 2018113。
本发明还保护鼠李糖乳杆菌TF318在制备抗抑郁产品中的应用。
本发明还保护鼠李糖乳杆菌TF318在制备治疗抑郁症的产品中的应用。
本发明还保护鼠李糖乳杆菌TF318在制备预防抑郁症的产品中的应用。
本发明还保护鼠李糖乳杆菌TF318在制备产品中的应用;
所述产品的功能为如下(a1)至(a20)中的至少一项:
(a1)升高单胺类神经递质含量;
(a2)升高脑组织中单胺类神经递质含量;
(a3)降低炎症因子含量;
(a4)降低血清中炎症因子含量;
(a5)降低丙二醛含量;
(a6)降低脑组织中丙二醛含量;
(a7)降低超氧化物歧化酶含量;
(a8)降低脑组织中超氧化物歧化酶含量;
(a9)降低皮质酮含量;
(a10)降低脑组织中皮质酮含量;
(a11)升高抑郁症患者单胺类神经递质含量;
(a12)升高抑郁症患者脑组织中单胺类神经递质含量;
(a13)降低抑郁症患者炎症因子含量;
(a14)降低抑郁症患者血清中炎症因子含量;
(a15)降低抑郁症患者丙二醛含量;
(a16)降低抑郁症患者脑组织中丙二醛含量;
(a17)降低抑郁症患者超氧化物歧化酶含量;
(a18)降低抑郁症患者脑组织中超氧化物歧化酶含量;
(a19)降低抑郁症患者皮质酮含量;
(a20)降低抑郁症患者脑组织中皮质酮含量。
所述单胺类神经递质为5-羟色胺和/或多巴胺和/或去甲肾上腺素。
所述炎症因子为TNF-α和/或IL-1β和/或NO。
本发明还保护一种抗抑郁产品,其活性成分为鼠李糖乳杆菌TF318。
本发明还保护一种治疗抑郁症的产品,其活性成分为鼠李糖乳杆菌TF318。本发明还保护一种预防抑郁症的产品,其活性成分为鼠李糖乳杆菌TF318。本发明还保护一种产品,其活性成分为鼠李糖乳杆菌TF318。
所述产品的功能为如下(a1)至(a20)中的至少一项:
(a1)升高单胺类神经递质含量;
(a2)升高脑组织中单胺类神经递质含量;
(a3)降低炎症因子含量;
(a4)降低血清中炎症因子含量;
(a5)降低丙二醛含量;
(a6)降低脑组织中丙二醛含量;
(a7)降低超氧化物歧化酶含量;
(a8)降低脑组织中超氧化物歧化酶含量;
(a9)降低皮质酮含量;
(a10)降低脑组织中皮质酮含量;
(a11)升高抑郁症患者单胺类神经递质含量;
(a12)升高抑郁症患者脑组织中单胺类神经递质含量;
(a13)降低抑郁症患者炎症因子含量;
(a14)降低抑郁症患者血清中炎症因子含量;
(a15)降低抑郁症患者丙二醛含量;
(a16)降低抑郁症患者脑组织中丙二醛含量;
(a17)降低抑郁症患者超氧化物歧化酶含量;
(a18)降低抑郁症患者脑组织中超氧化物歧化酶含量;
(a19)降低抑郁症患者皮质酮含量;
(a20)降低抑郁症患者脑组织中皮质酮含量。
所述单胺类神经递质为5-羟色胺和/或多巴胺和/或去甲肾上腺素。
所述炎症因子为TNF-α和/或IL-1β和/或NO。
以上任一所述药品可为但不限于如下剂型:胶囊、粉剂、片剂。所述药品还可包括其他药学上可以接受的赋形剂或稀释剂。制备粉剂的方法可为冷冻干燥或其它工艺。
本发明提供的鼠李糖乳杆菌TF318具有抗抑郁功能,可作为预防和治疗抑郁症的功能性益生菌,为临床干预和控制抑郁症等相关的精神类疾病提供新的思路,具有良好的产业前景。
附图说明
图1为实施例3的步骤四的结果。
图2为实施例3的步骤五的结果。
具体实施方式
以下的实施例便于更好地理解本发明,但并不限定本发明。下述实施例中的实验方法,如无特殊说明,均为常规方法。下述实施例中所用的试验材料,如无特殊说明,均为自常规生化试剂商店购买得到的。以下实施例中的定量试验,均设置三次重复实验,结果取平均值。
清洁级ICR雄性小鼠(18-22g):长春生物制品研究所。饲养环境:23±2℃,湿度50%-75%,自由摄取基础饲料和纯净水。基础饲料:长春生物制品研究所。
乳杆菌选择性培养基(LBS琼脂):青岛海博生物技术有限公司,货号HB0385-1。
利血平注射液(规格1mg/ml):广东邦民制药厂有限公司。
盐酸氟西汀胶囊:苏州中化药品工艺有限公司。
小鼠多巴胺(DA)酶联免疫分析(ELISA)试剂盒:上海江莱生物科技有限公司,货号JL-F11187。小鼠去甲肾上腺素(NE)酶联免疫分析(ELISA)试剂盒:上海江莱生物科技有限公司,货号JL-F13969。小鼠5-羟色胺(5-HT)酶联免疫分析(ELISA)试剂盒:上海江莱生物科技有限公司,货号JL-F12087。小鼠一氧化氮(NO)酶联免疫分析(ELISA)试剂盒:上海江莱生物科技有限公司,货号JL-F17342。小鼠丙二醛(MDA)酶联免疫分析(ELISA)试剂盒:上海江莱生物科技有限公司,货号JL13329。小鼠超氧化物歧化酶(SOD)酶联免疫分析(ELISA)试剂盒:上海江莱生物科技有限公司,货号:JL12237。小鼠皮质酮(CORT)酶联免疫分析(ELISA)试剂盒:上海朗顿生物科技有限公司,货号:BPE30590。Mouse TNF-αELISA MAXTMDeluxe,美国biolegend公司,货号:430904。Mouse IL-1βELISA MAXTMDeluxe,美国biolegend公司,货号:432604。
鼠李糖乳杆菌JAAS8是吉林省农业科学院畜产品加工团队于2007年从酸菜中分离得到的益生菌,该菌株可以分泌大量的胞外多糖和荚膜多糖。参考文献:Capsular andslime-polysaccharide production by Lactobacillus rhamnosus JAAS8 isolatedfrom Chinese sauerkraut Potential application in fermented milk products;鼠李糖乳杆菌JAAS8胞外多糖生物合成基因的克隆及生物信息学分析。
盐酸氟西汀溶液的制备方法:取盐酸氟西汀胶囊中的颗粒物,用0.5g/100ml羧甲基纤维素钠水溶液溶解。盐酸氟西汀的剂量以颗粒物计。
实施例1、菌株的分离、鉴定和保藏
一、菌株的分离
2016年8月,从吉林省长春市采集新生婴儿的新鲜粪便,挑取粪便中心样品并放入运输培养基中,加入1mL灭菌液体石蜡油密封,迅速置于冰盒内送至实验室进行分离。将酸菜样品和粪便样品梯度稀释后,分别采用MRS固体培养基、乳杆菌选择性培养基对样品中的乳杆菌进行分离,于厌氧条件下37℃培养48h,挑取平板上的典型菌落,划线培养,分离得到纯菌落。
将分离得到的各个菌株进行形态鉴定、生理生化鉴定以及分子鉴定,其中2株属于鼠李糖乳杆菌(Lactobacillus rhamnosus),依次命名为鼠李糖乳杆菌TF316、鼠李糖乳杆菌TF318。
二、菌株的鉴定
鼠李糖乳杆菌TF318的生理生化鉴定结果:革兰氏阳性,短杆状,在15℃及45℃环境下均能生长,过氧化氢酶阴性,接触酶阴性,无运动性,硝酸盐还原阴性,吲哚阴性,不产生硫化氢,不液化明胶。
鼠李糖乳杆菌TF318的API 50CH(法国梅里埃公司)鉴定结果:能利用利用D-核糖、D-半乳糖、D-葡萄糖、D-果糖、D-甘露糖、L-山梨糖、L-鼠李糖、卫矛醇、甘露醇、山梨醇、甲基-αD-吡喃葡萄糖苷、N-乙酰葡萄糖胺、苦杏仁苷、ARBULIN、七叶灵、柠檬酸铁、水杨苷、D-纤维二糖、D-麦芽糖、D-乳糖、D-蜜二糖、D-蔗糖、D-海藻糖、D-松三糖、淀粉、糖原、D-龙胆二糖、D-土伦糖、D-塔格糖、葡萄糖酸钾;而不利用甘露醇、赤藻糖醇、D-阿拉伯糖、L-阿拉伯糖、D-木糖、L-木糖、D-侧金盏花醇I、甲基-βD吡喃木糖苷、肌醇、甲基-αD-吡喃甘露糖苷、菊粉、D-棉子糖、木糖醇、D-来苏糖、D-岩藻糖、L-岩藻糖、D-阿拉伯醇、L-阿拉伯醇、2-酮基葡萄糖酸钾、5-酮基葡萄糖酸钾。
鼠李糖乳杆菌TF318的分子鉴定结果:16S rDNA序列如序列表的序列1所示。
三、菌株的保藏
鼠李糖乳杆菌(Lactobacillus rhamnosus)TF318,已于2018年03月11日保藏于中国典型培养物保藏中心(简称CCTCC,地址为:中国,武汉,武汉大学),保藏编号为CCTCC NO:M 2018113。
实施例2、鼠李糖乳杆菌TF318的抗抑郁功能
供试菌分别为:鼠李糖乳杆菌TF316(用TF316表示)、鼠李糖乳杆菌JAAS8(用JAAS8表示)和鼠李糖乳杆菌TF318(用TF318表示)。
一、菌悬液的制备
1、供试菌接种于液体MRS培养基,37℃静置培养16小时,然后4℃、6000rpm离心8min,收集菌体沉淀。
2、取步骤1得到的菌体沉淀,用无菌生理盐水悬浮,得到菌浓度为2×1010CFU/mL的菌悬液。
供试菌为TF316时,进行上述步骤得到的菌悬液命名为TF316菌悬液。
供试菌为JAAS8时,进行上述步骤得到的菌悬液命名为JAAS8菌悬液。
供试菌为TF318时,进行上述步骤得到的菌悬液命名为TF318菌悬液。
二、分组处理
试验动物为清洁级ICR雄性小鼠。
试验动物先进行连续3天的适应性饲养,然后随机分为6组,每组30只,处理如下:
对照组:连续21天每天灌胃一次生理盐水(单次单只的给予量为0.2mL),末次灌胃18小时后腹腔注射生理盐水(单只的给予量为0.1mL),腹腔注射4小时后处死试验动物;
模型组:连续21天每天灌胃一次生理盐水(单次单只的给予量为0.2mL),末次灌胃18小时后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg体重),腹腔注射4小时后处死试验动物;
阳性药物组:连续21天每天灌胃一次盐酸氟西汀溶液(单次给予盐酸氟西汀的剂量为10mg/kg体重,给予体积量为0.2mL),末次灌胃18小时后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg),腹腔注射4小时后处死试验动物;
TF318组:连续21天每天灌胃一次步骤一制备的TF318菌悬液(单次单只的给予量为0.2mL),末次灌胃18h后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg体重),腹腔注射4小时后处死试验动物;
TF316组:连续21天每天灌胃一次步骤一制备的TF316菌悬液(单次单只的给予量为0.2mL),末次灌胃18h后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg体重),腹腔注射4小时后处死试验动物;
JAAS8组:连续21天每天灌胃一次步骤一制备的JAAS8菌悬液(单次单只的给予量为0.2mL),末次灌胃18h后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg体重),腹腔注射4小时后处死试验动物。
三、抗抑郁功能鉴定
1、抑郁样行为检测
抑郁样行为的评价指标为眼睑下垂、出圈率和体温。
注射利血平注射液1小时后,将小鼠放在架子上观察15s,对小鼠眼睑下垂程度并进行评分:0分,眼睑未关闭;1分,眼睑关闭1/4;2分,眼睑关闭1/2;3分,眼睑关闭3/4;4分,眼睑全部关闭。
注射利血平注射液2小时后,将小鼠放入直径7.5cm的圆形白纸中央,观察15s后留在白纸上的小鼠数量,出圈率=(小鼠总数量-留在白纸上的小鼠数量)÷小鼠总数量。
注射利血平注射液4小时后,将小鼠体温计插入肛门1cm处测量体温。
抑郁样行为的检测结果见表1。
表1
眼睑下垂(分) | 出圈率(%) | 体温(℃) | |
模型组 | 96 | 10.8 | 31.9±0.61 |
对照组 | 0 | 100 | 36.9±0.37 |
阳性药物组 | 58 | 43.3 | 33.8±0.66<sup>*</sup> |
TF316组 | 82 | 23.3 | 31.8±0.84 |
TF318组 | 55 | 40.0 | 33.2±0.74<sup>*</sup> |
JAAS8组 | 68 | 30.0 | 32.4±0.67 |
模型组小鼠:注射利血平1小时后,小鼠出现小鼠精神萎靡、嗜睡的临床表现,眼睑下垂非常严重,眼睑睁开的程度小于1/4,眼睑下垂的分数为96分;注射利血平2h后,小鼠出现蜷缩、活动减少及腹泻现象,出圈率为10.8%;注射利血平4h后,小鼠体温下降,平均体温为31.9℃。
TF318组小鼠:注射利血平1小时后,小鼠眼睑下垂,但是与模型组小鼠相比程度有所减缓,眼睑下垂的平均分值为55分;注射利血平2h后,小鼠出现蜷缩、活动减少及腹泻现象,但与模型组相比有所减缓,出圈率为40.0%;注射利血平4h后,小鼠体温显著高于模型组小鼠,平均体温为33.2℃。
结果表明,鼠李糖乳杆菌TF318可以有效的对抗利血平诱导的抑郁样行为。鼠李糖乳杆菌TF316、鼠李糖乳杆菌JAAS8对于抑郁样行为有一定的改善作用,但效果显著劣于鼠李糖乳杆菌TF318。
2、脑组织中单胺类神经递质水平的检测
处死试验动物后,冰袋上取出脑组织,分离出海马和皮质组织,加入10倍体积的预冷的pH7.4、0.05M PBS缓冲液,匀浆,然后4℃、4000g/min离心20min,取上清液。采用试剂盒检测上清液中5-羟色胺、多巴胺和去甲肾上腺素。结果见表2。
表2
组别 | 5-HT(ng/ml) | DA(pg/ml) | NE(ng/ml) |
模型组 | 21.03±1.15 | 6.13±0.01 | 16.46±0.03 |
对照组 | 23.23±0.69* | 7.66±0.51* | 26.51±7.50** |
阳性药物组 | 25.39±0.84** | 7.75±1.69* | 23.15±0.56* |
TF316组 | 20.09±0.87 | 6.23±0.48 | 16.58±5.97 |
TF318组 | 23.21±2.13* | 7.63±0.81* | 25.73±7.85** |
JAAS8组 | 22.45±0.98 | 6.55±1.15 | 20.31±5.09 |
与对照组小鼠相比,模型组小鼠脑组织中5-HT、DA、NE的浓度显著减低(p<0.05)。与模型组小鼠相比,TF318组小鼠脑组织中5-HT、DA和NE浓度增高,差异显著(p<0.05)或极显著(p<0.01)。鼠李糖乳杆菌TF316、鼠李糖乳杆菌JAAS8有一定的改善作用,但效果显著劣于鼠李糖乳杆菌TF318。结果表明,灌胃鼠李糖乳杆菌TF318可以有效的缓解由于利血平注射而导致小鼠脑组织中单胺类神经递质浓度的下降趋势,说明该菌株具有抗抑郁的效果。
实施例3、鼠李糖乳杆菌TF318抗抑郁功效的验证
一、菌悬液的制备
1、鼠李糖乳杆菌TF318接种于液体MRS培养基,37℃静置培养至16小时,然后4℃、6000rpm离心8min,收集菌体沉淀。
2、取步骤1得到的菌体沉淀,用无菌生理盐水悬浮,得到菌浓度为2×1010CFU/mL的TF318菌悬液。
二、分组处理
试验动物为清洁级ICR雄性小鼠。
试验动物先进行连续3天的适应性饲养,然后随机分为4组,每组30只,处理如下:
对照组:连续21天每天灌胃一次生理盐水(单次单只的给予量为0.2mL),末次灌胃18小时后腹腔注射生理盐水(单只的给予量为0.1mL),腹腔注射4小时后处死试验动物;
模型组:连续21天每天灌胃一次生理盐水(单次单只的给予量为0.2mL),末次灌胃18小时后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg),腹腔注射4小时后处死试验动物;
阳性药物组:连续21天每天灌胃一次盐酸氟西汀溶液(单次给予盐酸氟西汀的剂量为10mg/kg,给予体积量为0.2mL),末次灌胃18小时后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg),腹腔注射4小时后处死试验动物;
TF318组:连续21天每天灌胃一次步骤一制备的TF318菌悬液(单次单只的给予量为0.2mL),末次灌胃18h后腹腔注射利血平注射液(给予利血平的剂量为4mg/kg),腹腔注射4小时后处死试验动物;
三、鼠李糖乳杆菌TF318降低小鼠血清中的炎症因子水平
处死试验动物前,摘眼球取血,分离血清,检测血清中的炎症因子(TNF-α、IL-1β和NO)。结果见表3。与对照组相比,模型组小鼠血清中TNF-α、IL-1β、NO水平明显升高。与模型组相比,TF318组小鼠血清中TNF-α、IL-1β水平和NO水平均呈不同程度降低。结果表明,鼠李糖乳杆菌TF318能明显缓解利血平诱导的小鼠炎症反应,降低小鼠血清中炎症因子水平。
表3
组别 | Tnf-a(ng/l) | ILl-β(ng/l) | NO(μmol/l) |
模型组 | 124.51±9.80 | 270.41±17.90 | 4.79±0.16 |
对照组 | 104.13±6.21** | 248.38±16.75 | 4.22±0.11 |
阳性药物组 | 111.30±7.03* | 247.78±12.47 | 4.24±0.09 |
TF318组 | 119.19±3.33* | 252.46±21.56 | 4.49±0.31 |
四、鼠李糖乳杆菌TF318降低小鼠脑组织中的氧化应激水平
氧化应激参与了慢性痛和抑郁的发病过程。
处死试验动物后,冰袋上取出脑组织,检测脑组织中丙二醛和超氧化物歧化酶含量。
结果见图1。与对照组相比,模型组小鼠脑组织中丙二醛和超氧化物歧化酶水平升高,差异极显著(P<0.01)。与模型组相比,TF318组小鼠脑组织中丙二醛和超氧化物歧化酶水平降低,差异极显著(P<0.01)。
五、鼠李糖乳杆菌TF318降低小鼠脑组织中的皮质酮含量
强烈刺激可使HAP轴兴奋,使得肾上腺合成分泌糖皮质激素增多,高浓度的皮质酮会诱发患者脑内海马神经元损伤,导致认知能力下降。
处死试验动物后,冰袋上取出脑组织,检测脑组织中皮质酮的含量。
结果见图2所示。与对照组相比,模型组小鼠脑组织中皮质酮水平显著升高。与模型组相比,TF318组小鼠脑组织中皮质酮水平降低。
SEQUENCE LISTING
<110> 吉林省农业科学院
<120> 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用
<130> GNCYX180907
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 1466
<212> DNA
<213> Lactobacillus rhamnosus
<400> 1
ttagacggct cgctccctaa aagggttacg ccaccggctt cgggtgttac aaactctcat 60
ggtgtgacgg gcggtgtgta caaggcccgg gaacgtattc accgcggcgt gctgatccgc 120
gattactagc gattccgact tcgtgtaggc gagttgcagc ctacagtccg aactgagaat 180
ggctttaaga gattagcttg acctcgcggt ctcgcaactc gttgtaccat ccattgtagc 240
acgtgtgtag cccaggtcat aaggggcatg atgatttgac gtcatcccca ccttcctccg 300
gtttgtcacc ggcagtctta ctagagtgcc caactaaatg ctggcaacta gtcataaggg 360
ttgcgctcgt tgcgggactt aacccaacat ctcacgacac gagctgacga caaccatgca 420
ccacctgtca ttttgccccc gaaggggaaa cctgatctct caggtgatca aaagatgtca 480
agacctggta aggttcttcg cgttgcttcg aattaaacca catgctccac cgcttgtgcg 540
ggcccccgtc aattcctttg agtttcaacc ttgcggtcgt actccccagg cggaatgctt 600
aatgcgttag ctgcggcact gaagggcgga aaccctccaa cacctagcat tcatcgttta 660
cggcatggac taccagggta tctaatcctg ttcgctaccc atgctttcga gcctcagcgt 720
cagttacaga ccagacagcc gccttcgcca ctggtgttct tccatatatc tacgcatttc 780
accgctacac atggagttcc actgtcctct tctgcactca agtttcccag tttccgatgc 840
acttcctcgg ttaagccgag ggctttcaca tcagacttaa aaaaccgcct gcgctcgctt 900
tacgcccaat aaatccggat aacgcttgcc acctacgtat taccgcggct gctggcacgt 960
agttagccgt ggctttctgg ttggataccg tcacgccgac aacagttact ctgccgacca 1020
ttcttctcca acaacagagt tttacgaccc gaaagccttc ttcactcacg cggcgttgct 1080
ccatcagact tgcgtccatt gtggaagatt ccctactgct gcctcccgta ggagtttggg 1140
ccgtgtctca gtcccaatgt ggccgatcaa cctctcagtt cggctacgta tcattgcctt 1200
ggtgagccgt tacctcacca actagctaat acgccgcggg tccatccaaa agcgatagct 1260
tacgccatct ttcagccaag aaccatgcgg ttcttggatt tatgcggtat tagcatctgt 1320
ttccaaatgt tatcccccac ttaagggcag gttacccacg tgttactcac ccgtccgcca 1380
ctcgttcaaa attaaatcaa gatgcaagca cctttcaata atcagaactc gttcgacttg 1440
catgtattag gcacgccgcc agcgtt 1466
Claims (4)
1.鼠李糖乳杆菌(Lactobacillus rhamnosus)TF318,其保藏编号为CCTCC NO:M2018113。
2.权利要求1所述鼠李糖乳杆菌TF318在制备抗抑郁药品中的应用。
3.权利要求1所述鼠李糖乳杆菌TF318在制备药品中的应用;
所述药品的功能为如下(a1)至(a10)中的至少一项:
(a1)升高脑组织中单胺类神经递质含量;
(a2)降低血清中炎症因子含量;
(a3)降低脑组织中丙二醛含量;
(a4)降低脑组织中超氧化物歧化酶含量;
(a5)降低脑组织中皮质酮含量;
(a6)升高抑郁症患者脑组织中单胺类神经递质含量;
(a7)降低抑郁症患者血清中炎症因子含量;
(a8)降低抑郁症患者脑组织中丙二醛含量;
(a9)降低抑郁症患者脑组织中超氧化物歧化酶含量;
(a10)降低抑郁症患者脑组织中皮质酮含量。
4.一种抗抑郁药品,其活性成分为权利要求1所述鼠李糖乳杆菌TF318。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810606721.5A CN108715822B (zh) | 2018-06-13 | 2018-06-13 | 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810606721.5A CN108715822B (zh) | 2018-06-13 | 2018-06-13 | 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108715822A CN108715822A (zh) | 2018-10-30 |
CN108715822B true CN108715822B (zh) | 2021-09-03 |
Family
ID=63912897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810606721.5A Active CN108715822B (zh) | 2018-06-13 | 2018-06-13 | 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108715822B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110066753B (zh) * | 2019-05-13 | 2020-01-07 | 吉林省农业科学院 | 植物乳杆菌dp189及其应用 |
CN114540245B (zh) * | 2022-03-17 | 2023-11-28 | 江南大学 | 一株同时具有缓解抑郁情绪及促进肠道分泌IgA功能的鼠李糖乳杆菌CCFM1228及其应用 |
CN116420831B (zh) * | 2023-06-01 | 2023-08-22 | 山东向日葵生物工程有限公司 | 一种鼠李糖乳杆菌sf-l30在制备改善机体血清素水平发酵饮品中的应用 |
CN116850213B (zh) * | 2023-07-24 | 2024-04-30 | 青岛东海药业有限公司 | 一种益生菌组合物及其应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060233752A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
US20060233762A1 (en) * | 2005-04-15 | 2006-10-19 | Mcmahon Robert J | Method for treating or preventing systemic inflammation in formula-fed infants |
HUP0700552A2 (en) * | 2007-08-27 | 2009-03-30 | Janos Dr Feher | Method and composition inhibiting inflammation |
CN102994432B (zh) * | 2012-12-26 | 2014-07-09 | 光明乳业股份有限公司 | 一种鼠李糖乳杆菌及其用途 |
-
2018
- 2018-06-13 CN CN201810606721.5A patent/CN108715822B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN108715822A (zh) | 2018-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108715822B (zh) | 一株鼠李糖乳杆菌及其在制备抗抑郁产品中的应用 | |
Li et al. | Synergy of Astragalus polysaccharides and probiotics (Lactobacillus and Bacillus cereus) on immunity and intestinal microbiota in chicks | |
KR102010207B1 (ko) | 세균 균주를 포함하는 조성물 | |
CN110205270B (zh) | 一种缓解养殖动物便秘的副干酪乳杆菌l9的应用 | |
KR20080068912A (ko) | 바실루스 츄린겐시스를 함유하는 유해균의 방제제 | |
US20210220415A1 (en) | Composition and uses thereof | |
Yoshida et al. | Oral administration of Lactobacillus plantarum Lq80 and Megasphaera elsdenii iNP‐001 induces efficient recovery from mucosal atrophy in the small and the large intestines of weaning piglets | |
CN117286077B (zh) | 一种防治急性放射性肠损伤的益生菌剂及其应用 | |
CN116855413B (zh) | 利用鼠李糖乳杆菌YSs069制备调节人体微生态平衡的生物活性物质及其应用 | |
US20210121538A1 (en) | Interactional Biosystem | |
CN112852670A (zh) | 一种婴儿双歧杆菌dh231及其发酵产物、应用和微生态制剂 | |
CN114699424B (zh) | 脆弱拟杆菌两性离子荚膜多糖或/和改性的两性离子荚膜多糖的新应用 | |
KR20240037981A (ko) | 생리학적으로 허용되는 효모 조성물 및 이의 용도 | |
CN115011513A (zh) | 一种增强免疫并调解肠胃控制脂肪及减肥排毒的乳酸菌粉 | |
RU2401111C1 (ru) | Препарат для лечения сальмонеллеза у молодняка сельскохозяйственных животных | |
CN108853081B (zh) | 穗花杉双黄酮在制备治疗鸡坏死性肠炎的药物中的用途 | |
CN108309969B (zh) | 鸢尾黄素在治疗鸡坏死性肠炎中的医用用途 | |
EP2681338B1 (en) | Sporulation-deficient Brevibacillus texasporus cells and methods for efficient and cost-effective inactivation and use thereof | |
CN116396891B (zh) | 嗜酸乳杆菌la-g80、两歧双歧杆菌bb-g90的益生菌组合物及在护肝方面的应用 | |
CN117384790B (zh) | 一株戊糖片球菌ks5及其在制备助睡眠药品中的应用 | |
CN117511773B (zh) | 一株粪肠球菌、复合菌剂及其应用 | |
JP6588742B2 (ja) | 免疫機能亢進剤 | |
Truter | Evidence-based Pharmacy Practice (EBPP): probiotics and prebiotics: evidence-based pharmacy practice | |
JP2020184909A (ja) | 血糖降下剤、及び、該血糖降下剤を含有する飲食品 | |
CN117511773A (zh) | 一株粪肠球菌、复合菌剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |